Sanofi's GLP-1 drug tops Victoza in after-meal glucose control; Novo's diabetes treatment spurs weight loss;

> Sanofi's ($SNY) lixisenatide, marketed in Europe as Lyxumia, outperformed Novo Nordisk's ($NVO) Victoza in lowering post-prandial blood sugar when both were added to the insulin Lantus. News

> Eli Lilly ($LLY) and Boehringer Ingelheim announced that a fixed-dose combination of the SGLT-2 blocker empagliflozin and the DPP-4 inhibitor linagliptin reduced blood glucose better than each agent alone. More

> A 3-mg dose of Novo Nordisk's liraglutide (marketed as Victoza) showed significantly greater weight loss than placebo in a 56-week trial on obese patients with Type 2 diabetes. The company has submitted FDA and European applications to get the drug approved as a weight-loss treatment. Item

Suggested Articles

A new, late-phase analysis of cholesterol-lowering inclisiran showed that it was able to cut LDL levels by 51% after nearly a year and a half.

The data were highly anticipated, especially since the two partners continued testing after the compound missed its endpoints in phase 2 studies.

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.